OA + PD + MS

Osteoarthritis (OA)

• A slowly progressive, noninflammatory disorder of synovial joints characterized by gradual loss of articular cartilage, thickening of cartilage at joint margins, and formation of bony outgrowths called osteophytes. The normally smooth cartilage becomes dull, yellow, granular, softer, and less elastic, making it less able to resist wear.

• OA is not a normal part of aging, but age is a major risk factor. Cartilage damage may begin around ages 20–30, most adults show some changes by about age 40, symptoms often do not appear until after age 50, and by age 65 nearly half of adults report arthritis.

• Risk increases with obesity, prior joint injury such as ACL damage, repetitive kneeling/stooping, genetic factors, and decreased estrogen after menopause. As cartilage breaks down faster than it can be repaired, joint surfaces become uneven, ROM decreases, and pain develops; early pain/stiffness may result from secondary synovitis, while later pain occurs when cartilage is lost and bone surfaces rub together.

Osteoarthritis Clinical Manifestations: Joints

• Joint pain is the main symptom and usually worsens with activity. Early in the disease, rest relieves pain, but advanced disease may cause pain at rest or at night.

• Stiffness occurs after rest or inactivity, called the gelling phenomenon. Morning stiffness usually resolves within 30 minutes, which helps distinguish OA from inflammatory disorders such as RA.

• Crepitation is common, especially in the knee. OA is usually asymmetric and commonly affects weight-bearing joints, the cervical/lumbar spine, MTP joints, DIP/PIP joints, and the thumb MCP joint.

Osteoarthritis Clinical Manifestations: Deformity

• Heberden nodes occur at the DIP joints and Bouchard nodes occur at the PIP joints due to osteophyte formation and joint-space loss. Heberden nodes may appear as early as age 40.

• Knee OA may cause varus deformity (bowlegged) from medial compartment disease or valgus deformity (knock-kneed) from lateral compartment disease.

• Advanced hip OA may cause shortening of the affected leg as the joint space narrows.

Osteoarthritis Clinical Manifestations: Systemic

• Fatigue, fever, and organ involvement are not present because OA is primarily a noninflammatory joint disorder.

• The absence of systemic manifestations helps distinguish OA from inflammatory disorders such as rheumatoid arthritis.

Osteoarthritis: Diagnostic Studies

• X-rays are the main imaging study used to confirm OA and stage joint damage. Findings may include joint-space narrowing, increased bone density, and osteophytes, but the severity of x-ray changes does not always match the patient’s pain.

• Bone scan, CT, or MRI can detect earlier joint changes but are not routinely used because of cost. Synovial fluid is typically clear yellow with little or no inflammation and can help distinguish OA from inflammatory arthritis.

• No specific laboratory test or biomarker diagnoses OA. ESR is usually normal, with only slight elevation during acute inflammation; routine blood tests are mainly used to rule out other conditions or obtain baseline values before treatment.

Osteoarthritis: Interprofessional Care

• OA has no cure, so treatment focuses on controlling pain and inflammation, preventing disability, and maintaining or improving joint function.

• Management may combine patient education with behavioral, psychosocial, and physical interventions plus topical, oral, or intraarticular medications.

• No disease-modifying osteoarthritis drug has been approved to stop or slow OA progression despite ongoing research.

Osteoarthritis: Drug Therapy

• NSAIDs are first-line treatment and are similarly effective at equivalent doses. Most inhibit both COX-1 and COX-2; blocking COX-2 reduces inflammation, while blocking COX-1 increases the risk for GI irritation and bleeding.

• Topical options include capsaicin, which decreases pain by interfering with substance P, and diclofenac gel. Patients taking an oral NSAID should avoid using a topical NSAID at the same time because this increases adverse-effect risk.

• GI protection such as misoprostol may be added for patients at risk for NSAID-related GI effects. Warfarin plus an NSAID greatly increases bleeding risk; celecoxib may be considered for selected patients.

• Intraarticular corticosteroids may be used for local inflammation and swelling, but systemic corticosteroids are not used because they may accelerate disease. Hyaluronic acid injections are not recommended by the ACR or AAOS.

Osteoarthritis: Surgical Therapy

• Surgery is considered when conservative treatment no longer controls symptoms and the patient develops severe pain, loss of joint function, or increasing dependence with self-care.

• Reconstructive procedures such as total hip or knee replacement may be used to restore function and relieve pain.

Osteoarthritis: Nursing Assessment

• Assess the type, location, severity, frequency, and duration of joint pain and stiffness, including what improves or worsens symptoms and how they affect ADLs.

• Examine affected joints for tenderness, swelling, decreased ROM, and crepitation; compare with the opposite unaffected joint when possible.

• Review current pain-management strategies and their effectiveness. Functional assessment questionnaires may be repeated over time to track disease progression and response to treatment.

Osteoarthritis: Clinical Problems

• Common clinical problems include pain, musculoskeletal problems, and impaired role performance.

• Pain and loss of joint function can interfere with mobility, ADLs, work, and the patient’s ability to fulfill usual family or social roles.

Osteoarthritis: Planning

• Maintain or improve joint function by balancing appropriate rest with regular activity and exercise.

• Use joint-protection strategies and assistive measures to improve activity tolerance and reduce stress on affected joints.

• Maintain independence with self-care and optimal role function while using both drug and nondrug strategies to achieve satisfactory pain control.

Osteoarthritis Implementation: Health Promotion

• Focus on modifiable risk factors by maintaining a healthy weight, reducing occupational or recreational joint stress, and avoiding smoking.

• Encourage regular exercise with strength and endurance training and teach safety measures that reduce joint trauma during work, sports, and physical activity.

Osteoarthritis Implementation: Ambulatory Care

• Most care is outpatient and may involve primary care, rheumatology, nursing, OT, and PT; hospitalization is usually only needed for joint surgery.

• Teach pain management, body mechanics, correct use of assistive devices, joint protection, energy conservation, nutrition, weight/stress management, and exercise.

• Emphasize that OA is usually a localized disease and does not typically progress to severe deforming arthritis.

Osteoarthritis Implementation: Heat and Cold Applications

• Use ice for acute inflammation or swelling, although it is used less often than heat in OA.

• Heat is especially useful for stiffness because it improves blood flow and flexibility; options include hot packs, whirlpool baths, ultrasound, and paraffin wax baths.

Osteoarthritis Implementation: Nutrition Therapy

• Weight reduction is a critical treatment goal for overweight patients because excess body weight increases stress on weight-bearing joints.

• Help the patient evaluate dietary habits and make changes that support reaching and maintaining a healthy weight.

Osteoarthritis Implementation: Exercise

• Aerobic conditioning, ROM exercises, and strengthening of muscles around affected joints help maintain function and reduce disability.

• Warm up before exercise to reduce injury risk; balance exercises can improve stability and fall prevention.

• Tai Chi may improve strength and balance and can be adapted for patients of different ages and mobility levels.

Osteoarthritis Implementation: Rest and Joint Protection

• Balance rest with activity and rest affected joints during periods of acute inflammation.

• Splints or braces may maintain joints in a functional position and stabilize painful or inflamed joints.

• Reduce joint stress by avoiding prolonged standing, kneeling, or squatting with knee OA and using assistive devices such as a cane, walker, or crutches when needed.

Osteoarthritis Implementation: Role Performance

• Modify the home and work environment to improve safety and independence, such as removing throw rugs, adding rails/grab bars and night-lights, and using supportive shoes or elevated toilet seats.

• Include caregivers and family in goal setting and teaching, and encourage continued use of prescribed therapies and assistive devices.

• For sexual activity, alternative positions, timing, analgesics, or a warm bath beforehand may reduce pain and stiffness and improve comfort.

Multiple Sclerosis (MS)

• A chronic, unpredictable, progressive, degenerative disorder of the CNS characterized by disseminated demyelination of nerve fibers in the brain and spinal cord.

• Onset is usually between ages 20–40, although it can occur at any age. People diagnosed at age 50 or older often have a more progressive course, and women are affected about 2–3 times more often than men.

• Disease severity varies widely, from little permanent impairment to severe progressive disability. MS is more common farther from the equator and in people of Northern European ancestry; adequate vitamin D levels may help reduce risk.

Multiple Sclerosis: Etiology and Pathophysiology

• The exact cause is unknown and likely involves genetic susceptibility plus environmental triggers. MS is an autoimmune process driven mainly by activated T cells; about 15% of patients have a blood relative with the disease.

• Activated T cells cross the blood-brain barrier and trigger inflammation against myelin, causing demyelination and slowed nerve conduction. Repeated inflammation eventually damages oligodendrocytes and axons, leading to permanent neurologic loss.

• MS is characterized by chronic inflammation, demyelination, and gliosis with plaque formation throughout the CNS. Life expectancy is reduced by about 7 years, and death is often related to infection or complications of immobility such as pneumonia.

Multiple Sclerosis: Clinical Manifestations

• Symptoms vary depending on the area of CNS involvement and may develop gradually over months or years or progress rapidly. Common neurologic findings include blurred/double vision, red-green color distortion, weakness, numbness/tingling, poor coordination, balance problems, tremors, dizziness, and severe fatigue.

• Lhermitte’s sign is an electric shock-like sensation down the spine or limbs with neck flexion. Cerebellar findings may include nystagmus, ataxia, dysarthria, and dysphagia; the “MS hug” is painful tightness from intercostal and abdominal muscle spasms.

• Bowel, bladder, sexual, cognitive, and emotional changes are common. Constipation is typical; a spastic bladder causes urgency/frequency/incontinence, while a flaccid bladder causes retention. Cognitive changes often affect concentration, multitasking, short-term memory, processing speed, and word finding, while general intelligence is usually preserved.

Multiple Sclerosis: Diagnostic Studies

• No single test confirms MS. MRI with contrast of the brain and spinal cord may show plaques, inflammation, atrophy, and tissue destruction.

• CSF may show increased IgG and oligoclonal bands, indicating CNS inflammation. Evoked potential testing may show delayed nerve conduction from the eyes or ears to the brain.

• Diagnostic criteria require evidence of at least 2 demyelinating lesions in different CNS locations, at least 2 attacks occurring at different times, and exclusion of other diagnoses.

Multiple Sclerosis: Drug Therapy

• There is no cure; treatment uses disease-modifying drugs (DMDs) to suppress or modify immune activity, slow progression, and prevent relapses. They are most effective when started early. Common DMDs include interferon β-1a/β-1b, glatiramer acetate, teriflunomide, fingolimod, siponimod, dimethyl fumarate, cladribine, and monoclonal antibodies.

• With β-interferons, rotate injection sites, monitor for depression and suicidal thoughts, use sun protection, and expect flu-like symptoms when therapy begins. Teriflunomide can cause severe liver toxicity; cladribine increases cancer risk; dimethyl fumarate and fingolimod can cause PML.

• IV corticosteroids treat acute exacerbations by reducing inflammation and edema and speeding recovery, but they do not reverse residual neurologic damage. Other drugs treat specific symptoms, such as amantadine/modafinil for fatigue, oxybutynin for bladder spasms, bethanechol for urinary retention, and dalfampridine to improve walking speed.

Multiple Sclerosis: Other Therapies

• Spasticity may be treated with stretching, physical therapy, baclofen, intrathecal medication pumps, or Botox. Severe refractory spasticity may require procedures such as neurectomy, rhizotomy, cordotomy, or dorsal-column stimulation.

• Tremors that do not respond to medication may be treated surgically with thalamotomy or deep brain stimulation (DBS).

• Exercise and physical therapy can improve function when the patient is not having an exacerbation by reducing spasticity, improving coordination, and strengthening unaffected muscles. Water exercise is especially helpful because buoyancy improves movement and control.

Multiple Sclerosis Nursing Management: Assessment

• Assess for weakness, fatigue, numbness/tingling, ataxia, spasticity, tremor, hyperreflexia, visual changes, vertigo, dysarthria, dysphagia, bowel/bladder problems, sexual dysfunction, and pressure injuries.

• Review triggers and history such as recent infection, stress, pregnancy, temperature extremes, family history, and adherence to medications.

• Assess coping and psychosocial status, including depression, anger, euphoria, social isolation, and ability to perform ADLs.

Multiple Sclerosis Nursing Management: Clinical Problems

• Common problems include musculoskeletal impairment, fatigue, difficulty coping, and impaired urinary elimination.

• Other concerns may include decreased mobility, self-care limitations, bowel dysfunction, skin breakdown, and psychosocial problems depending on the patient’s deficits.

Multiple Sclerosis Nursing Management: Planning

• Maximize neuromuscular function and maintain independence with ADLs for as long as possible.

• Manage fatigue, support psychosocial well-being, and help the patient adjust to the chronic and unpredictable disease course.

• Reduce factors that trigger exacerbations and help the patient recognize worsening symptoms early.

Multiple Sclerosis Nursing Management: Implementation

• Help identify and avoid triggers such as infection, trauma, stress, childbirth, live-virus vaccines, climate changes, and overheating; balance activity with rest and avoid excessive fatigue.

• During exacerbations or immobility, prevent respiratory complications, UTIs, and pressure injuries. Manage bladder dysfunction and constipation with appropriate medications, self-catheterization if needed, activity, fluids, and fiber.

• Teach medication effects, side effects/interactions, healthy diet, limited caffeine, infection prevention, and the need to report the first signs of an exacerbation.

Multiple Sclerosis Nursing Management: Evaluation

• Maintain or improve muscle strength and mobility.

• Maintain urinary continence or effectively manage bladder dysfunction.

• Maintain independence in ADLs and make appropriate health and lifestyle changes to manage MS.

Parkinson Disease (PD)

• A chronic, progressive neurodegenerative disorder characterized by bradykinesia, muscle rigidity, resting tremor, and gait changes. It is the most common form of parkinsonism.

• Risk increases with age, with an average onset around age 70; about 4% of patients are diagnosed before age 50.

• Men are about 1.5 times more likely than women to develop PD.

Parkinson Disease: Etiology and Pathophysiology

• The exact cause is unknown and likely involves both genetic and environmental factors. Risk may increase with traumatic brain injury and exposure to substances such as manganese, pesticides, herbicides, industrial solvents, and other chemicals.

• Degeneration of dopamine-producing neurons in the substantia nigra causes decreased dopamine and disrupts the normal dopamine-acetylcholine balance in the basal ganglia, impairing smooth, purposeful movement. Symptoms usually do not appear until about 60–80% of dopamine-producing neurons are lost.

• Lewy bodies, abnormal protein clumps, are commonly found in the brain. Genetics also plays a role, especially in early-onset disease; parkinsonism can mimic PD and may result from certain drugs, toxins, stroke, tumor, infection, trauma, or other neurologic disorders.

Parkinson Disease: Clinical Manifestations

• Onset is gradual and may begin on only one side of the body. Early findings can include a mild resting tremor, flattened affect, slowed ADLs, decreased arm swing, or shoulder rigidity that may be mistaken for arthritis.

• The classic motor findings are tremor, rigidity, bradykinesia, and postural instability. Tremor is usually worse at rest and improves with purposeful movement; “pill-rolling” tremor is characteristic. Rigidity may be cogwheel-like, while bradykinesia causes masked face, drooling, stooped posture, decreased arm swing, and a shuffling/festinating gait.

• Later findings include propulsion or retropulsion with increased fall risk, hypokinetic dysarthria and hypophonia, and difficulty stopping movement. Nonmotor symptoms may include depression, anxiety, fatigue, constipation, urinary problems, erectile dysfunction, cognitive changes, pain, and sleep disturbances.

Parkinson Disease: Complications

• Dysphagia can lead to malnutrition and aspiration. Progressive weakness and immobility increase the risk for pneumonia, UTIs, pressure injuries, and other complications of reduced mobility.

• Orthostatic hypotension and loss of postural reflexes greatly increase fall and injury risk, so environmental fall hazards should be minimized.

• Other complications include dyskinesias, worsening weakness, depression, hallucinations or psychosis, and dementia; dementia is associated with increased mortality.

Parkinson Disease: Diagnostic Studies

• No single diagnostic test confirms PD; diagnosis is based mainly on history and clinical manifestations.

• Clinical diagnosis generally requires at least 2 of the 4 major findings: tremor, rigidity, bradykinesia, and postural instability, typically with asymmetric onset.

• Improvement with levodopa or a dopamine agonist supports the diagnosis. MRI and CT are usually normal and help rule out other disorders; a DaTscan may help assess dopamine function and distinguish PD from similar conditions.

Parkinson Disease: Drug Therapy

• Carbidopa/levodopa (Sinemet) is the primary treatment for symptomatic PD. Levodopa crosses the blood-brain barrier and is converted to dopamine; carbidopa prevents peripheral breakdown so more levodopa reaches the brain. It improves symptoms but does not stop disease progression.

• Long-term levodopa may cause dyskinesias and unpredictable “on/off” periods. Dopamine agonists such as pramipexole, ropinirole, rotigotine, and apomorphine directly stimulate dopamine receptors; monitor for orthostatic hypotension, hallucinations, dizziness, and excessive sleepiness.

• MAO-B inhibitors increase dopamine by decreasing its breakdown, while COMT inhibitors prolong levodopa action and are used when doses wear off. Anticholinergics such as benztropine and trihexyphenidyl reduce acetylcholine activity and mainly help tremor and rigidity.

Parkinson Disease: Surgical Therapy

• Surgery is considered when medications no longer adequately control symptoms or when severe motor complications develop. Deep brain stimulation (DBS) is the most common procedure.

• DBS places electrodes in areas such as the thalamus, globus pallidus, or subthalamic nucleus and connects them to a programmable generator in the chest. It can improve motor function and reduce dyskinesias and is preferred because it is reversible and programmable.

• Ablation procedures destroy targeted brain tissue that produces abnormal impulses; examples include thalamotomy, pallidotomy, gamma knife surgery, and MRI-guided focused ultrasound.

Parkinson Disease Nursing Management: Assessment

• Assess motor findings such as bradykinesia, resting tremor, cogwheel rigidity, shuffling gait, stooped posture, impaired postural reflexes, frequent falls, and loss of dexterity or micrographia.

• Assess dysphagia, drooling, weight loss, constipation, urinary problems, orthostatic hypotension, sleep problems, pain/cramping, depression, hallucinations, cognitive impairment, and ability to perform ADLs.

• Review history of CNS trauma, cerebrovascular disease, infections, or toxin exposure and medications that can cause parkinsonism, such as haloperidol, phenothiazines, methyldopa, and amphetamines.

Parkinson Disease Nursing Management: Clinical Problems

• Common problems include neurologic impairment, compromised nutrition, risk for injury, impaired communication, and difficulty coping.

• Dysphagia, immobility, postural instability, and cognitive changes can further increase the risk for aspiration, falls, malnutrition, and loss of independence.

Parkinson Disease Nursing Management: Planning

• Maximize neurologic and physical function while maintaining independence with ADLs for as long as possible.

• Prevent injury and complications such as falls, aspiration, contractures, and immobility-related problems.

• Promote adequate nutrition, communication, mobility, and overall physical and psychosocial well-being.

Parkinson Disease Nursing Management: Implementation

• Encourage regular exercise and PT to reduce muscle atrophy, contractures, and constipation and improve mobility. OT can improve self-care, while speech therapy can address speech and swallowing problems.

• Promote safety and independence by removing rugs/clutter, using an elevated toilet seat and supportive chairs, simplifying clothing, allowing extra time for ADLs, and using assistive devices as needed.

• For dysphagia or fatigue with eating, provide easy-to-chew foods, bite-sized pieces, adequate fiber, and up to 6 small meals daily. Protein can reduce levodopa absorption, so protein may be concentrated later in the day if prescribed.

• Monitor depression, anxiety, cognitive decline, sleep problems, and caregiver strain. Provide education, emotional support, counseling resources, and community support as the disease progresses.

Parkinson Disease Nursing Management: Evaluation

• Maintain optimal muscle function and use assistive devices safely and appropriately.

• Maintain adequate nutrition and swallowing without aspiration.

• Use effective communication methods and maintain as much independence and interaction with others as possible.